{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:40:46Z","timestamp":1791819646887,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["FoUI-1023897"],"award-info":[{"award-number":["FoUI-1023897"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["24 3826 Pj"],"award-info":[{"award-number":["24 3826 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["FoUI-975235"],"award-info":[{"award-number":["FoUI-975235"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["20 0156\\u2009F"],"award-info":[{"award-number":["20 0156\\u2009F"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Cancer Research Foundations of Radiumhemmet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejca.2025.116201","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:07:09Z","timestamp":1766794029000},"page":"116201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-4771","authenticated-orcid":false,"given":"Hildur","family":"Helgadottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-5958","authenticated-orcid":false,"given":"Lars","family":"Ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav J.","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0291-2279","authenticated-orcid":false,"given":"Rasmus","family":"Mikiver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116201_bib1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib4","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116201_bib5","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116201_bib6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116201_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant Pembrolizumab versus IFNalpha2b or Ipilimumab in Resected High-Risk Melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.116201_bib8","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib9","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib10","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib14","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116201_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115485","article-title":"Neoadjuvant immunotherapy for patients with resectable stage III\/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL)","volume":"224","author":"Nelson","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116201_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116201_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after Introduction of Adjuvant Treatment in Stage III Melanoma: A Nationwide Registry-Based study","author":"Helgadottir","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2025.116201_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2016.02.029","article-title":"Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register","volume":"59","author":"Lyth","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116201_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104295","article-title":"Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028","volume":"10","author":"Donia","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116201_bib22","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116201_bib23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"_7","key":"10.1016\/j.ejca.2025.116201_bib24","first-page":"S356","article-title":"Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant therapies for resected stage II-III melanoma","volume":"33","author":"Zara","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116201_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16058","article-title":"Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022","volume":"5","author":"Mousavi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2025.116201_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (Doublet Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial-ECOG-ACRIN EA6134","volume":"39","author":"Atkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116201_bib27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41467-023-44475-6","article-title":"Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial","volume":"15","author":"Ascierto","year":"2024","journal-title":"Nat Commun"},{"issue":"_7","key":"10.1016\/j.ejca.2025.116201_bib28","first-page":"S808","article-title":"Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116201_bib29","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116201_bib30","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"},{"issue":"42","key":"10.1016\/j.ejca.2025.116201_bib31","first-page":"1","article-title":"Current state of adjuvant therapy for melanoma: less is more, or more is better?","author":"Lao","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:46:55Z","timestamp":1781686015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"alternative-id":["S0959804925010871"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116201","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116201"}}